| Jan 8, 2026 | AGTC | $75.0M Series C | — | Oxford Science Enterprises, Rusty Kelley, Advent Life Sciences, Forbion |
| Jul 9, 2024 | AGTC | $170.0M Series B | Wouter Joustra | Dominic Schmidt, Oxford Science Enterprises, Elisa Petris, Cariad Chester, University of Oxford |
| Jun 1, 2024 | iOnctura | $86.0M Series B | Alice Renard | Keno Gutierrez, INKEF Capital, Johnson & Johnson Innovation, Hakan Goker, M Ventures (Merck), Seroba Life Sciences, Taiho Ventures |
| Jun 12, 2023 | AGTC | $120.0M Other Equity | — | Ekaterina Smirnyagina, Chris Hollowood |
| Apr 1, 2023 | Mosaic Therapeutics | $28.0M Series A | Cambridge Innovation Capital, Magdalena Jonikas | — |
| May 18, 2022 | SwanBio Therapeutics | $56.0M Series B | Mass General Brigham Ventures, Chris Hollowood | — |
| Apr 5, 2022 | Resolution Therapeutics | $13.1M Series A Extension | Edward Hodgkin | — |
| Apr 1, 2022 | OMass Therapeutics | $95.0M Series B | GV, Northpond Ventures, Sanofi Ventures | Forbion, Versant Ventures, Ysios Capital, Oxford Science Enterprises, Oxford University, Edward Hodgkin |
| Dec 1, 2021 | Anaveon | $120.0M Series B | Forbion | High-Tech Gründerfonds, Kurma Partners, Therese Liechtenstein, Novartis Venture Fund, Omega Funds, Pfizer Venture Investments, Pontifax Venture Capital, Seroba Life Sciences, Vincent Brichard, Tim Anderson, Novartis, Martin Murphy |
| Nov 3, 2021 | Clade Therapeutics | $87.0M Series A | Martin Murphy | Bristol Myers Squibb, Neil White, Ryan Cinalli |
| Nov 1, 2021 | Quell Therapeutics | $160.0M Series B | Fidelity Management & Research Company, Rachel Mears, Wayne Holman, Houman Ashrafian | Lightstone Ventures, Soffinova Partners, SV Health Investors, Judith Hartley MBE, Janus Henderson Investors, Monashee Investment Management, Point72, Martin Murphy, Tekla Capital Management |
| Mar 1, 2021 | Gyroscope Therapeutics | $150.0M Series C | Forbion | Abingworth, Cambridge Innovation Capital, Krishna Yeshwant, Sofinnova Investments, Westlake Village BioPartners, Fosun Pharma, Chris Hollowood, Tetragon Financial Group, T. Rowe Price Associates, Undisclosed healthcare focused fund |
| Nov 19, 2020 | Achilles Therapeutics | $69.8M Series C | Boxer Capital, OrbiMed | Forbion, Invus, Perceptive Advisors, RA Capital Management, Redmile Group |
| Sep 14, 2020 | Neogene Therapeutics | $110.0M Series A | Oleg Nodelman, Rafaèle Tordjman, Martin Murphy | Polaris Partners, Pontifax, TPG, Two River, Vida Ventures |
| Apr 24, 2020 | SwanBio Therapeutics | $52.0M Series A Extension | Partners Innovation Fund, Syncona | — |
| Nov 21, 2019 | Azeria Therapeutics | $41.4M Series B | Magdalena Jonikas | CRT Pioneer Fund |
| Sep 3, 2019 | Achilles Therapeutics | $120.8M Series B | Derek DiRocco | Rogier Rooswinkel, Invus, Perceptive Advisors, Redmile Group, Martin Murphy |
| May 20, 2019 | Quell Therapeutics | $44.6M Series A | Martin Murphy | UCL |
| Feb 1, 2019 | Anaveon | $35.0M Series A | Dominic Schmidt | Novartis Venture Fund, Florian Müllershausen |
| Sep 1, 2017 | Autolus | $80.0M Series C | — | Accel, Accomplice VC, GV, Soffinova Partners, Stride VC, Ben Holmes, Joe Anderson, Bihua Chen, Nextech Invest, Martin Murphy, Woodford Investment Management |
| Jun 1, 2017 | Nightstar Therapeutics | $45.0M Series C | — | Mott Family Capital, Ali Behbahani, OrbiMed, New Enterprise Associates, Redmile Group, Chris Hollowood, Wellington Management |
| Nov 1, 2016 | Achilles Therapeutics | $16.1M Other Equity | Cancer Research Horizons, Syncona, UCL | Francis Crick Institute, UCL Business |
| Mar 1, 2016 | Cambridge Epigenetix | $21.0M Series B | GV | Andreessen Horowitz, Craft Ventures, Creandum, Dawn Capital, Floodgate, F-Prime Capital Partners, Greylock, Erik Nordlander, Khosla Ventures, LAUNCH, Sequoia Capital, Vendep Capital, Webb Investment Network, Dharmesh Shah, Nikolaj Nyholm, Pete Moore, University of Cambridge |
| Nov 1, 2015 | Nightstar Therapeutics | $35.0M Series B | David Mott | Mott Family Capital, Ali Behbahani, OrbiMed |
